The DOI matches its Crossref record; 269 of the 291 references it cites were found in a registry or an index.
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Abstract
Irritable bowel syndrome (IBS) is a highly prevalent, chronic disorder that significantly reduces patients' quality of life. Advances in diagnostic testing and in therapeutic options for patients with IBS led to the development of this first-ever American College of Gastroenterology clinical guideline for the management of IBS using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Twenty-five clinically important questions were assessed after a comprehensive literature search; 9 questions focused on diagnostic testing; 16 questions focused on therapeutic options. Consensus was obtained using a modified Delphi approach, and based on GRADE methodology, we endorse the following: We suggest that a positive diagnostic strategy as compared to a diagnostic strategy of exclusion be used to improve time to initiating appropriate therapy. We suggest that serologic testing be performed to rule out celiac disease in patients with IBS and diarrhea symptoms. We suggest that fecal calprotectin be checked in patients with suspected IBS and diarrhea symptoms to rule out inflammatory bowel disease. We recommend a limited trial of a low fermentable oligosaccharides, disacchardies, monosaccharides, polyols (FODMAP) diet in patients with IBS to improve global symptoms. We recommend the use of chloride channel activators and guanylate cyclase activators to treat global IBS with constipation symptoms. We recommend the use of rifaximin to treat global IBS with diarrhea symptoms. We suggest that gut-directed psychotherapy be used to treat global IBS symptoms. Additional statements and information regarding diagnostic strategies, specific drugs, doses, and duration of therapy can be found in the guideline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eleven additional studies evaluated the effects on pain intensity but were unable to be pooled and had mixed findings.17,21,29,35,38,44,71,73,81,96,146”
From Adjunctive use of hypnosis for clinical pain: a systematic review and meta-analysis (2024) · cites this paper as [73]
In the citing paper
“A review of international guidelines reveals that peppermint oil is the only plant-based therapy consistently acknowledged across adult and pediatric recommendations.”
From Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines (2026) · cites this paper as [10]
In the citing paper
“These guidelines discouraged consumption of insoluble fiber from sources such as beans, nuts, and grains [47] or whole grains [48], and they discouraged intake of foods with high oligosaccharide content (for example, legumes, chickpeas, and lentils [49]).”
In the citing paper
“Other herbal treatments are not recommended; they are only mentioned in some systematic reviews [10].”
From Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines (2026) · cites this paper as [10]
Citations
Cites
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244 · cited 2×
“Once the pattern of stool consistency is determined, subtype decisions can be made according to the Rome IV criteria (4): a. IBS-C: .25% of bowel movements associated with BSFS 1 or 2 with BSFS 6 or 7 occurring less than 25%. b. IBS-D:.25% of bowel movements associated with BSFS 6 or 7 with less than 25% of bowel move…”
MethodLacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationHolmes, G. K. T., & Cooke, W. T. (1984) · Cited by 2,638
Burks, A. W., James, J. M., & Eigenmann, P. (1951) · Cited by 2,562
Rome IV—Functional GI Disorders: Disorders of Gut-Brain Interaction
Drossman, D. A., & Hasler, W. L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.035 · Cited by 1,928
Going from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis
Singh, P., Arora, A., Strand, T. A., Leffler, D. A., Catassi, C., Green, P. H., Kelly, C. P., Ahuja, V., & Makharia, G. K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.06.037 · Cited by 1,743
ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease
Rubio-Tapia, A., Hill, I. D., Kelly, C. P., Calderwood, A. H., & Murray, J. A. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.79 · Cited by 1,681
Carbohydrate quality and human health: a series of systematic reviews and meta-analyses
Reynolds, A., Mann, J., Cummings, J., Winter, N., Mete, E., & Te Morenga, L. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31809-9 · Cited by 1,630 · cited 1×
“most experts recommend 25–35 g of total fiber intake per day (123).”
Background
Research works printed but not linked: 6
- 2016, Fed Regist, 81, 33581
- Carling, 1989, Short term treatment of irritable bowel syndrome: A placebo-controlled trial of peppermint oil against hyoscyamine, OPMEAR, 34, 55
- 2008, FDA approves lubiprostone (Amitiza) for women with IBS with constipation, Medpage Today
- Boerner, 1988, Wirksamkeit und vertraglichkeit eines antidepressivuns beim colon irritabile, Therapiewoche, 38, 201
- Vij, 1991, Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients, Indian J Psychiatry, 33, 243
- Bergmann, 1991, [Die therapie des colon irritabile mit trimipramin (Herphonal): Eine kontrollierte studie], Z Klin Med, 46, 1621
Cited by
Peery, A. F., Kelly, C. R., Kao, D., Vaughn, B. P., Lebwohl, B., Singh, S., Imdad, A., & Altayar, O. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.008 · Cited by 258
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management
Staudacher, H. M., Black, C. J., Teasdale, S. B., Mikocka-Walus, A., & Keefer, L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00794-z · Cited by 249
Self-citationSasso, J. M., Ammar, R. M., Tenchov, R., Lemmel, S., Kelber, O., Grieswelle, M., & Zhou, Q. A. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00127 · Cited by 204
ACG Clinical Guideline Update: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Barnes, E. L., & Long, M. D. (2025) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003463 · Cited by 194
“Several studies have con fi rmed its utility in di ff erentiating IBD fromirritable bowelsyndrome (IBS) usingcut-o ff sthatvaryfrom6 to 280 mcg/g of stool (53).”
Self-citationChang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S., Greer, K. B., Hanson, B., Harris, L. A., Ko, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.214 · Cited by 185
Self-citation
Metadata
- Authors
- Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B.
- Affiliations
- Mayo Clinic (US)
- Cedars-Sinai Medical Center (US)
- Northwestern University (US)
- University of Michigan (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of North Carolina at Chapel Hill (US)
- University of North Carolina at Charlotte (US)
- Corresponding author
- Lacy, Brian E.
- ORCID
- Venue
- American Journal of Gastroenterology
- Published
- 2020-12-14
- Volume
- 116
- Issue
- 1
- Pages
- 17-44
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W3112460492
- Semantic Scholar
- ac3c4d9e3ec7ef485bd23006b8eb5c07e33eae11
- Cited by
- 893
- References
- 291
- Citations by year
- 2026: 197 · 2025: 146 · 2024: 175 · 2023: 148 · 2022: 138 · 2021: 88
- FWCI
- 81.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, IBS management, IBS diagnosis, diagnostic testing, celiac disease screening, fecal calprotectin, inflammatory bowel disease exclusion, FODMAP diet, chloride channel activator, rifaximin, irritable bowel syndrome with constipation, diarrhea-predominant irritable bowel syndrome
- MeSH terms
- Guanylyl Cyclase C Agonists, Rifaximin, Celiac Disease, Constipation, Delphi Technique, Diagnosis, Differential, Diarrhea, Diet Therapy, Feces, Gastroenterology, Gastrointestinal Agents, Humans, Hypnosis, Serologic Tests, Societies, Medical, Inflammatory Bowel Diseases, Cognitive Behavioral Therapy, Disease Management, Leukocyte L1 Antigen Complex, Irritable Bowel Syndrome, Chloride Channel Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ACG Clinical Guideline: Management of Irritable Bowel Syndrome. https://app.cochat.ai/papers/10.14309/ajg.0000000000001036
- The paper
- Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000001036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.